Copyright
©The Author(s) 2015.
World J Hepatol. Feb 27, 2015; 7(2): 213-225
Published online Feb 27, 2015. doi: 10.4254/wjh.v7.i2.213
Published online Feb 27, 2015. doi: 10.4254/wjh.v7.i2.213
Table 1 Dosage modification for patients with renal impairment
| Creatinine clearance | Pegylated-interferon alfa-2a | Pegylated-interferon alfa-2b | Ribavirin |
| 30-50 mL/min | 180 μg/wk | 1.125 μg/kg per week (25% reduction) | Alternating doses; 200 mg and 400 mg every other day |
| < 30 mL/min | 135 μg/wk (25%-45% reduction) | 0.75 μg/kg per week (50% reduction) | 200 mg/d |
| Hemodialysis | 135 μg/wk (25%-45% reduction) | 0.75 μg/kg per week (50% reduction) | 200 mg/d |
- Citation: Bunchorntavakul C, Maneerattanaporn M, Chavalitdhamrong D. Management of patients with hepatitis C infection and renal disease. World J Hepatol 2015; 7(2): 213-225
- URL: https://www.wjgnet.com/1948-5182/full/v7/i2/213.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i2.213